LUGELA in Dermatology
The use of LUGELA in dermatology has a direct clinical and laboratory basis. In a dissertation study by N. V. Glonti involving 200 patients with eczema, the effectiveness of oral and topical application of natural healing water was established. Clinical improvement was accompanied by reduced inflammation, cessation of weeping, decreased itching, epithelialization of affected areas, decreased vascular permeability, and favorable changes in mineral metabolism indicators.
The most substantiated regimen combines a course of oral LUGELA intake with topical treatment of affected areas. The oral course provides systemic effects of the natural mineral complex. Topical application acts directly on the area of inflammation, exudation, or tissue damage.
The Skin as an Active Physiological System
The skin is not a passive covering, but a complex organ performing barrier, immune, vascular, metabolic, and thermoregulatory functions.
Its restoration depends on the coordinated work of several processes:
- keratinocyte differentiation and renewal;
- maintenance of the epidermal barrier;
- regulated inflammatory response;
- condition of capillaries and microcirculation;
- formation of new intercellular matrix;
- epithelialization of damaged surfaces;
- mineral and protein metabolism;
- local immune defense.
The calcium gradient of the epidermis regulates keratinocyte maturation, formation of the stratum corneum, and restoration of the skin barrier. Disruption of this gradient accompanies epidermal damage, and calcium-dependent cell signaling participates in restoring its structure [6, 7].
This fundamental physiological principle explains the importance of mineral metabolism for skin condition, but direct proof of the action of a specific therapeutic agent requires clinical data. Such data on LUGELA were obtained in the study by N. V. Glonti.
N. V. Glonti's Clinical Study
The dissertation by N. V. Glonti titled "Therapy of Eczema with Natural Healing Water LUGELA" is a key specialized scientific work on the dermatological use of LUGELA.
The study involved 200 patients with various forms of eczema. To determine control physiological indicators, an additional 27 practically healthy individuals were examined.
Before treatment, sodium, calcium, and potassium levels in the blood were determined for all patients. Clinical results were compared with laboratory indicators and vascular permeability status.
Effectiveness was evaluated according to specific criteria:
- severity of inflammatory changes;
- cessation of weeping;
- reduction of itching;
- rate of epithelialization;
- timing of clinical improvement;
- duration of remission;
- frequency of relapse;
- changes in mineral blood composition;
- dynamics of vascular permeability.
Thus, the study's conclusions are based not on individual testimonials or subjective physician assessment but on systematized clinical, functional, and laboratory data.
Results of Oral Use
Glonti established the efficacy of oral LUGELA intake in patients with eczema during exacerbation.
Compared with a 10% pharmacy calcium chloride solution, oral LUGELA showed higher therapeutic activity. The author concluded that the action of the natural water is determined not by calcium chloride alone but by the sum of its components.
Clinical improvement was accompanied by favorable changes in mineral metabolism indicators. Simultaneously, inflammation and capillary permeability decreased.
This concurrence of clinical and laboratory results confirms the systemic nature of LUGELA's action. The oral course affects not only the skin surface but also internal physiological processes related to dermatosis progression.
Results of Topical Use
In Glonti's study, topical application of LUGELA at a 1:1000 dilution in eczema exacerbation led to rapid cessation of exudation.
Cessation of weeping is an important clinical outcome. Exudation reflects inflammation activity, increased vascular permeability, and fluid leakage into damaged tissues. Its reduction indicates the process is moving toward restoration and epithelialization.
The author recommended topical use of LUGELA as an independent local therapy, especially in pronounced weeping. Repeated use during eczema recurrence also provided good therapeutic results.
Established Sequence of Therapeutic Action
The study results form a logical chain of interrelated changes:
- Reduced capillary permeability.
- Decreased fluid leakage into inflamed tissues.
- Weeping stops.
- Decreased intensity of inflammatory response.
- Itching and irritation weaken.
- Conditions for epithelialization are established.
- Integrity of the skin barrier is restored.
- Clinical improvement is consolidated by favorable changes in mineral metabolism.
This sequence explains LUGELA's action in eczema through specific vascular, metabolic, and restorative processes.
Eczema as a Proven Clinical Area
Eczema is a dermatological area where LUGELA has a direct specialized evidence base.
The dissertation confirms:
- effectiveness of oral intake during exacerbation;
- therapeutic efficacy of topical application;
- rapid cessation of exudation;
- reduction of inflammatory manifestations;
- positive epithelialization dynamics;
- decreased vascular permeability;
- favorable mineral metabolism changes;
- effectiveness of repeated course during relapse;
- advantage of oral LUGELA over studied calcium chloride solution.
Based on the accumulated results, N. V. Glonti recommended LUGELA for treating patients with eczema.
Other Dermatological Fields
The 2023 medical conclusion includes skin and subcutaneous tissue diseases in the list of LUGELA application areas.
The instruction provides for oral and topical use in:
- psoriasis;
- neurodermatitis;
- eczema;
- vasculitis;
- urticaria;
- trophic ulcers;
- bedsores;
- diabetic foot syndrome;
- postoperative wounds;
- burns;
- other skin and soft tissue injuries.
LUGELA in Tissue Damage and Restoration
Healing of damaged skin includes inflammation, new tissue formation, epithelialization, and reconstruction of the restored area. Calcium signaling participates in cell migration, keratinocyte function, formation of intercellular contacts, and restoration of the epidermal barrier [7].
In this system, LUGELA is used in two complementary ways:
- orally, for systemic effects of the natural mineral complex;
- topically, for treating the area of damage or inflammation.
In bedsores, trophic ulcers, and diabetic foot syndrome, topical LUGELA is part of complex wound care. It does not replace wound surface cleansing, infection control, offloading the affected limb, blood supply assessment, and correction of underlying disease.
In diabetic foot, offloading the ulcer area, local wound management, infection control, and vascular status assessment remain essential treatment components [8].
In burns, topical application is performed after cessation of damaging factor exposure, cooling of the affected area, and determination of burn depth and area. Extensive and deep burns require specialized medical care [9].
Oral Course
For skin diseases, a monthly oral course of LUGELA is a basic condition.
Recommended scheme:
- four bottles of 235 ml for one month;
- single adult dose does not exceed 10 ml;
- interval between doses about five hours;
- one-two glasses of warm water are drunk 30 minutes before meals;
- dose is not increased independently.
The oral course forms the systemic foundation of application. Topical treatment complements it with direct action on the pathological area.
Topical Treatment
The modern instruction provides two main methods.
Spraying
LUGELA is sprayed onto the affected surface until evenly moistened. The treated area is left open until fully absorbed and dried.
After drying, the surface is covered with loose sterile gauze in one or two layers for contamination protection. Tight bandaging and hermetic sealing are not used as they create a greenhouse effect and increase inflammation.
Gauze Application
A sterile gauze pad is soaked with LUGELA and applied to the treated area for 25–30 minutes. After removal, the surface is left open to dry completely.
If necessary, the area is covered with loose sterile gauze. The dressing should not compress tissues or impede air circulation.
For eczema, psoriasis, and other chronic dermatoses, treatment is carried out twice daily, combined with the oral course.
For deep wounds, infected ulcers, diabetic foot, postoperative injuries, and burns, the treatment method is agreed upon with the medical wound management plan.
Objective Assessment of Results
Effectiveness is evaluated by measurable clinical signs:
- reduction of lesion area;
- cessation of weeping;
- severity of swelling and redness;
- decreased itching intensity;
- reduction of discharge;
- appearance of healthy granulation tissue;
- rate of epithelialization;
- condition of wound edges;
- absence of infection signs;
- duration of remission;
- frequency of relapses.
For chronic wounds, sequential photographs under consistent conditions, measurement of defect area and depth, assessment of discharge, and surrounding skin condition are used.
Such monitoring turns subjective impressions into documented clinical dynamics.
Safety of Use
Contraindications to oral LUGELA intake are:
- hypercalcemia;
- individual intolerance to components.
With topical use, individual skin reaction must be monitored. Increased pain, rapid spread of redness, purulent discharge, unpleasant odor, elevated tissue or body temperature require medical evaluation, as they indicate active infection or necrosis.
Academic Conclusion
LUGELA has a well-established scientific basis for use in dermatology.
The main evidence source is the clinical study by N. V. Glonti conducted on 200 patients with eczema. The author established the efficacy of oral and topical LUGELA use, confirmed clinical results with laboratory indicators, and demonstrated the connection of therapeutic action with mineral metabolism and vascular permeability.
Topical use showed rapid cessation of exudation. Oral intake noted decreased inflammatory manifestations, epithelialization, favorable mineral metabolism changes, and higher therapeutic activity compared to the studied pharmacy calcium chloride solution.
Modern medical documents expand LUGELA dermatological uses to include skin diseases, bedsores, trophic ulcers, postoperative wounds, burns, and diabetic foot syndrome.
The most consistent scheme combines systemic course intake and topical treatment. Oral application influences mineral and vascular-metabolic components of the pathological process. Topical application targets directly the inflammation, exudation, or tissue damage area.
The scientific credibility of LUGELA in dermatology is based not on general assumptions about the benefits of minerals but on clinically registered changes: cessation of weeping, reduction of inflammation and itching, epithelialization, decreased vascular permeability, and normalization of studied mineral metabolism parameters.
Main Sources
- Glonti N. V. Therapy of Eczema with Natural Healing Water LUGELA. Dissertation for Candidate of Medical Sciences degree.
- Javakhishvili D. V. LUGELA Mineral Water: Characteristics and Healing Properties. Tbilisi: Gruzmedgiz, 1953.
- Medical conclusion on the use of natural mineral water LUGELA. 2023.
- Balneological conclusion of the North Caucasus Federal Scientific Clinical Center of FMBA Russia. 2023.
- Instruction for oral and topical use of therapeutic mineral water LUGELA.
- Lee S. E., Lee S. H. Skin Barrier and Calcium. Annals of Dermatology. 2018;30(3):265–275.
- Subramaniam T. et al. The Role of Calcium in Wound Healing. International Journal of Molecular Sciences. 2021;22(12):6486.
- International Working Group on the Diabetic Foot. Guidelines on the prevention and management of diabetes-related foot disease. 2023.
- World Health Organization. Burns. Fact sheet. 2023.